Cardiac Myosin Activation Across the Lifespan: Age-Based Efficacy and Safety of Omecamtiv Mecarbil in HFrEF
Highlights
- Omecamtiv mecarbil (OM) demonstrated consistent clinical benefits in reducing cardiovascular death or first heart failure events across the entire age spectrum (18–85 years).
- The treatment effect was particularly robust in patients with severe heart failure, regardless of whether they were under or over 65 years of age.
- Unlike many traditional inotropes, OM showed no significant interaction with age regarding safety outcomes, including blood pressure and heart rate stability.
- In the GALACTIC-HF trial, more than half of the participants (54.5%) were aged 65 or older, providing high-quality evidence for geriatric heart failure management.
Background
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.